Wim J. Tamminga

645 citations

13 papers · 492 indexed · h-index 10

Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 8
Endocrinology, Diabetes and Metabolism
- Hormonal Regulation and Hypertension 2
Pharmacology
- Pharmacogenetics and Drug Metabolism 8
Pediatrics, Perinatology and Child Health
- Pharmaceutical studies and practices 5
Cardiology and Cardiovascular Medicine
Economics and Econometrics
- Health Systems, Economic Evaluations, Quality of Life 3
Anesthesiology and Pain Medicine
- Anesthesia and Sedative Agents 2
Statistics and Probability
- Statistical Methods in Clinical Trials 2
Psychiatry and Mental health
- Schizophrenia research and treatment 2
Public Health, Environmental and Occupational Health
- Ethics in Clinical Research 1

Co-authors: J. H. G. Jonkman B. Oosterhuis J. Wemer Dick de Zeeuw Jaap Wieling Joachim Stangier Lou de Leij Bob Wilffert
Cited by: Pharmacology Endocrinology, Diabetes and Metabolism
Journals: British Journal of Clinical Pharmacology (3 papers)European Journal of Clinical Pharmacology (5 papers)The Journal of Clinical Pharmacology (1 paper)
Partner nations: Netherlands Sweden Germany

In The Last Decade

Wim J. Tamminga

12 papers receiving 472 citations

Peers

Countries citing papers authored by Wim J. Tamminga

Since Specialization

Citations

This map shows the geographic impact of Wim J. Tamminga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim J. Tamminga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim J. Tamminga more than expected).

Fields of papers citing papers by Wim J. Tamminga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim J. Tamminga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim J. Tamminga. The network helps show where Wim J. Tamminga may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Wim J. Tamminga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wim J. Tamminga Line = papers co-authored together Wim J. Tamminga links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work
1	Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach British Journal of Clinical Pharmacology ·Jules A. A. C. Heuberger,Perry de Jongh,Ewoud‐Jan van Hoogdalem,Wim J. Tamminga,Pieter de Graeff,Geert Jan Groeneveld	2025	0
2	Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings PubMed ·Khalid Abou Farha,Corine Baljé‐Volkers,Wim J. Tamminga,Izaak den Daas,Sandra van Os	2014	14
3	Serial CSF sampling over a period of 30 h via an indwelling spinal catheter in healthy volunteers: headache, back pain, tolerability and measured acetylcholine profile European Journal of Clinical Pharmacology ·Izaak den Daas,Johan Wemer,Khalid Abou Farha,Wim J. Tamminga,Theo de Boer,Rob Spanjersberg,Michel Struys,Anthony Absalom	2012	8
4	The impact of Cytochrome P450‐2D6 genotype on the use and interpretation of therapeutic drug monitoring in long‐stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice Pharmacoepidemiology and Drug Safety ·Hans Mulder,A.J. Herder,Frederik W. Wilmink,Wim J. Tamminga,Svetlana V. Belitser,Toine C. G. Egberts	2005	23
5	Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study European Journal of Clinical Pharmacology ·Wim J. Tamminga,Johan Wemer,B. Oosterhuis,Anthonius de Boer,Stan Vranckx,Ben F. H. Drenth,Dick de Zeeuw,Lou F. M. H. de Leij,J. H. G. Jonkman	2003	28
6	The prevalence of CYP2C19 genotypes in a population of healthy Dutch volunteers and apparent gender differences in phenotypes British Journal of Clinical Pharmacology ·Wim J. Tamminga,Johan Wemer,B. Oosterhuis,Dick de Zeeuw,Lou F. M. H. de Leij,J. H. G. Jonkman	2002	2
7	The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers European Journal of Clinical Pharmacology ·Wim J. Tamminga,J. Wemer,B. Oosterhuis,R. de Zeeuw,Lou de Leij,J. H. G. Jonkman	2001	81
8	An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19 European Journal of Clinical Pharmacology ·Wim J. Tamminga,Johan Wemer,B. Oosterhuis,Jan P. Brakenhoff,M. Gerrits,Dick de Zeeuw,Lou F. de Leij,J. H. G. Jonkman	2001	37
9	Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge Journal of Cardiovascular Pharmacology ·Joachim Stangier,Chung‐An P. F. Su,P. N. M. van Heiningen,Thomas Meinicke,Jan Jaap van Lier,Henrieke de Bruin,Wim J. Tamminga,J. H. G. Jonkman	2001	36
10	Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra‐individual reproducibility and occurrence of adverse events British Journal of Clinical Pharmacology ·Wim J. Tamminga,Johan Wemer,B. Oosterhuis,Jaap Wieling,Daan J. Touw,Dick de Zeeuw,Lou F. M. H. de Leij,J. H. G. Jonkman	2001	14
11	Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. Therapeutic Drug Monitoring ·Jaap Wieling,Wim J. Tamminga,Elly Sakiman,B. Oosterhuis,Johan Wemer,J. H. G. Jonkman	2000	13
12	Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [¹⁴C]Telmisartan in Healthy Volunteers The Journal of Clinical Pharmacology ·Joachim Stangier,Jochen Schmid,Dietrich Türck,Heinz Switek,A. Marjan G. Verhagen,Pierre Peeters,Sjoerd P. van Marle,Wim J. Tamminga,Frans A. E. Sollie,J. H. G. Jonkman	2000	129
13	CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences European Journal of Clinical Pharmacology ·Wim J. Tamminga,J. Wemer,B. Oosterhuis,Jaap Wieling,Bob Wilffert,L.F.M.H. de Leij,Dick de Zeeuw,J. H. G. Jonkman	1999	107

About Wim J. Tamminga

Wim J. Tamminga is a scholar working on Pharmacology, Anesthesiology and Pain Medicine and Pediatrics, Perinatology and Child Health, having authored 13 papers that have together received 492 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (8 papers), Pharmaceutical studies and practices (5 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Anesthesia and Sedative Agents (2 papers), Statistical Methods in Clinical Trials (2 papers), Schizophrenia research and treatment (2 papers), Hormonal Regulation and Hypertension (2 papers) and Ethics in Clinical Research (1 paper). The work is most often cited by research in Pharmacology (264 citations), Endocrinology, Diabetes and Metabolism (90 citations) and Pharmacology (88 citations). Wim J. Tamminga has collaborated with scholars based in Netherlands, Sweden and Germany. Frequent co-authors include J. H. G. Jonkman, B. Oosterhuis, J. Wemer, Dick de Zeeuw, Jaap Wieling, Joachim Stangier, Lou de Leij, Bob Wilffert, Pierre Peeters and Johan Wemer. Their work appears in journals such as British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact